Agios Pharmaceuticals Inc

Financials

Cash from operating activities -290.76 M-407.32 M-309.48 M-296.06 M-389.84 M-372.98 M -372.98 M Cash from investing activities 75.75 M1.25 B243.26 M239.57 M363.44 M377.18 M 377.18 M Cash from financing activities 261.52 M-765.77 M2.35 M5.43 M14.44 M8.68 M 8.68 M Free cash flow -305.67 M-413.06 M-314.36 M-297.06 M-391.53 M-377.29 M -377.29 M

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals Inc

News

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress

Agios Pharm earnings beat by $0.09, revenue topped estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharm set to report earnings amid thalassemia drug rollout

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Williams to Report Q4 Earnings: What Surprise Awaits Investors?

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript